Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA Read more about Zai Lab Announces NDA for Ripretinib Granted Priority Review by China’s NMPA
Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates Read more about Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates
Ripretinib Becomes the First Unregistered Drug in Mainland China Approved for the Named Patient Program Outside the Pilot Zone of Hainan Province Read more about Ripretinib Becomes the First Unregistered Drug in Mainland China Approved for the Named Patient Program Outside the Pilot Zone of Hainan Province
China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor Read more about China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China Read more about Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China
Dr. Samantha Du shares her perspectives in the book “Biotechnology in the Time of COVID-19” Read more about Dr. Samantha Du shares her perspectives in the book “Biotechnology in the Time of COVID-19”
Zai Lab Announces Presentations at June Conferences Read more about Zai Lab Announces Presentations at June Conferences
Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections Read more about Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Read more about China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA Read more about Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA